Dublin, Ireland - ABB, the leading power and automation technology group, has been chosen by Yamanouchi Ireland Co., Limited (YICL) to upgrade their Dublin production plant with Industrial IT technology. This plant will be used in the production of one of Yamanouchi's new treatments for urinary incontinence.
"The combination of technology, along with the need to meet the most stringent requirements of regulatory authorities, such as the US FDA, delivery schedule and competitive pricing were decisive in Yamanouchi's selection of ABB," said John Lehane, Technical Services Manager at Yamanouchi Ireland Co., Limited. "We were seeking a technology partner as well as a project solution and ABB's Industrial IT technology is capable of supporting us in our heavily regulated environment."
ABB's scope of supply includes a complete FDA 21 CFR part 11 compliant process control system comprising: Produce IT Batch recipe management system, Inform IT Information Manager plant historian, and SattLine DCS along with Control IT local and S900 hazardous area remote I/O. The contract also includes the complete design, system engineering, testing, validation and customer training.
Yamanouchi Ireland Co., Ltd is the Irish subsidiary of Yamanouchi Pharmaceutical Co., Ltd (YPCL), which is Japan's second largest pharmaceutical company employing over 7,500 people worldwide. Yamanouchi has extensive operations outside Japan in China, Europe and the USA. The manufacture of this new active pharmaceutical in the Dublin plant will augment Yamanouchi's franchise as a leader in urinary medicine.
ABB (www.abb.com) is a leader in power and automation technologies that enable utility and industry customers to improve performance while lowering environmental impacts. The ABB group of companies operates in more than 100 countries and employs about 145,000 people.
FOR MORE INFORMATION CONTACT:
ABB Marketing Communications
Tel: +1 440 585 6830
Tel : +363 (0)86 8516 073